In this insight report the author comments on global M&A activity and trends across different sectors and markets and offer our view on how the market may develop in the months ahead.
Beginning on 1 January 2014, French pharmacists are now legally permitted to substitute a biosimilar for the prescribed (reference) biological medicine as long as the prescribing physician has not marked the prescription as “non-substitutable.” According to the new law, substitution is allowed only when initiating a course of treatment, and if the biosimilar belongs to the same group as the prescribed product, known as a “similar biologic group.” The criteria for inclusion in a “similar biologic group” have yet to be defined by the French healthcare authority (ANSM).
This article explores the role of business in resisting and denouncing all forms of bribe solicitation and extortion. It is a chapter in a book titled International Chamber of Commerce Ethics and Compliance Training Handbook which can be purchased <a href="http://www.iccbooks.com/Product/ProductInfo.aspx?id=698">here</a>. You can learn more about the handbook <a href=" http://www.iccwbo.org/News/Articles/2013/Ethics-and-compliance-training-book-responds-to-global-need/">here</a>.
This Top Ten provides an overview of the purpose, development, structure and implications of the the US National Institute of Standards and Technology (NIST) 2013 Preliminary Cybersecurity Framework.
This Top Ten focuses on protections needed in a ground lease in order for a leasehold mortgagee to consider the ground lease financeable.
This Quick Counsel will focus on commenting the new data protection regulation in Colombia and its implications for the companies that handle data.
A review of new rules by the Brazilian National Council of Private Insurance related to the adjusted new worth of companies for insurance purposes.
This article is a report on a survey on corporate responsibility.
The market for pharmaceutical products and medical devices in Brazil is definitely taking off. The Brazilian Public Health System (SUS) is continually increasing pharmaceutical assistance, as new drugs become available, as a result of the development of new public health policies. Read this chapter on Brazil to learn more.